Longevity Biotech is a Philadelphia-based biotechnology company specializing in the development of breakthrough therapeutics using their innovative Hybridtide peptide scaffold. With a focus on preclinical development, their pipeline includes programs in neuroscience and diabetes, utilizing their proprietary databases to optimize absorption parameters for oral peptide delivery. Their unique composition of natural and non-natural amino acids allows for precise modulation of intracellular signal cascades, demonstrating signal bias and enabling fine-tuning of molecular biology pathways.
By leveraging their Hybridtide technology, Longevity Biotech offers a platform for collaboration, providing market-leading stability in any biological environment without compromising functionality. Their expertise in oral peptide platform formulation ensures the critical parameters of stability, solubility, and absorption are optimized for commercial success. With a commitment to artisan biology, they can modulate molecular biology pathways and target different states of proteins, making them a valuable partner in intracellular targeting, delivery, and binding affinity tuning.
Generated from the website
